| FGF-23 and vitamin D: don't shoot the messenger? | |
| | |
MedLine Citation:
|
PMID: 22523113 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The discovery of fibroblast growth factor-23 (FGF-23) as a key regulator of phosphate and vitamin D metabolism has forced a rethink about the mineral and bone disorder of chronic kidney disease (CKD). FGF-23 powerfully predicts adverse cardiovascular outcomes in patients with CKD and an important question is whether treatment regimens should now be tailored to address FGF-23 levels in addition to those of calcium, phosphate, parathyroid hormone and vitamin D. Nevertheless, despite the known action of active vitamin D therapies to increase FGF-23, this should probably still form an important part of the management of patients with hyperparathyroidism and perhaps at low doses of essentially all patients with advanced renal disease. |
| | |
Authors:
|
Richard S Fish; John Cunningham |
Related Documents
:
|
2406863 - Bismuth subsalicylate in the treatment of gastritis due to campylobacter pylori. 9171793 - Computed tomographic evaluation of gastric emphysema--a report of three cases. 6497353 - Brain electrical activity in patients with presenile and senile dementia of the alzheim... |
Publication Detail:
|
Type: Comment; Editorial Date: 2012-04-20 |
Journal Detail:
|
Title: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Volume: 27 ISSN: 1460-2385 ISO Abbreviation: Nephrol. Dial. Transplant. Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-05-31 Completed Date: 2012-10-02 Revised Date: 2013-05-27 |
Medline Journal Info:
|
Nlm Unique ID: 8706402 Medline TA: Nephrol Dial Transplant Country: England |
Other Details:
|
Languages: eng Pagination: 2137-9 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Density Conservation Agents
/
therapeutic use* Ergocalciferols / therapeutic use* Female Fibroblast Growth Factors / metabolism* Humans Hydroxycholecalciferols / therapeutic use* Hyperparathyroidism, Secondary / drug therapy*, metabolism* Male |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Ergocalciferols; 0/Hydroxycholecalciferols; 0/fibroblast growth factor 23; 131918-61-1/paricalcitol; 62031-54-3/Fibroblast Growth Factors; URQ2517572/alfacalcidol |
| Comments/Corrections | |
Comment On:
|
Nephrol Dial Transplant. 2012 Jun;27(6):2263-9
[PMID:
22140123
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of IRS-1 and IRS-2 genes polymorphisms with polycystic ovary syndrome: a meta-analysis.
Next Document: Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects...